Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), acquired Halo Pharma, a leading dosage form Contract Development and Manufacturing Organization (CDMO) located in Whippany, New Jersey and Mirabel, Québec, Canada.
Fasken represented Cambrex with respect to the acquisition of the Canadian entities of Halo in Canada.
The acquisition of Halo by Cambrex added formulation development and finished dosage manufacturing capabilities to Cambrex’s then existing global API manufacturing network. This acquisition creates a leading small molecule CDMO with a broad range of capabilities and a robust customer base.
The Fasken team, which acted as Canadian counsel to Cambrex, was led by Sylvie Bourdeau and included Andrew Alleyne, Kadiatou Sow, Frédérique Tremblay, Mathieu Gagné, Jean-Raphael Champagne, Dara Jospé, Mitchell Thaw, Paul Cabana, Pierre-Olivier Charlebois, Jean-Philippe Therriault and Emilie Paquin-Holmested.
